Observes patient satisfaction and safety of atezolizumab in routine care
Studies how people with lung cancer or liver cancer experience atezolizumab given under the skin.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
Key facts
- Where
- Auderghem, Ghent, Haine-Saint-Paul, Liège, Merksem, and Mont-godinne, BelgiumSee the 6 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you 18 years old or older?
- Which best describes your lung cancer?
Source: NCT07284121, who can take part
Where in Belgium
- CHIRECAuderghem, BelgiumTaking people
- AZ Sint Lucas (Sint Lucas)Ghent, BelgiumTaking people
- CHU HELORA - Hôpital de la Louvière - Site JolimontHaine-Saint-Paul, BelgiumTaking people
- CHC MontLégiaLiège, BelgiumTaking people
- ZNA Jan PalfijnMerksem, BelgiumTaking people
- CHU UCL Mont-GodinneMont-godinne, BelgiumTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hoffmann-La Roche
- Trial code
- NCT07284121
- Record updated
- 6 November 2026
- Original description
This is a non-interventional, multi-country, multi-centre, multicohort, primary data collection study, designed to assess patients' reported satisfaction with Atezolizumab Subcutenous (SC) treatment and Health-related Quality of Life (HRQoL), as well as the effectiveness and safety of Atezolizumab SC in participants treated for selected approved indications in routine clinical practice.Read full original descriptionShow less
A Non-Interventional, Multicenter, Multicohort Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Subcutaneous Atezolizumab in Participants Treated in Routine Clinical Practice
This is a non-interventional, multi-country, multi-centre, multicohort, primary data collection study, designed to assess patients' reported satisfaction with Atezolizumab Subcutenous (SC) treatment and Health-related Quality of Life (HRQoL), as well as the effectiveness and safety of Atezolizumab SC in participants treated for selected approved indications in routine clinical practice.
Inclusion: Participants must have one of the following confirmed diagnoses for which atezolizumab is approved in the local SmPC:; Early stage NSCLC following complete resection and platinum-based chemotherapy with a high risk of recurrence and PD-L1 expression on ≥ 50% of TC and with no EGFR-mutant or ALK-positive NSCLC; Metastatic stage NSCLC with PD-L1 expression on ≥ 50% TC or ≥ 10% tumor infiltrating immune cells (IC) and with no EGFR-mutant or ALK-positive NSCLC not previously treated; Extensive-stage small cell lung cancer (ES-SCLC) not previously treated; Advanced or unresectable HCC not previously treated with systemic therapy; Should not have received > 4 prior cycles of IV Atezolizumab.
Exclusion: Not receiving treatment with Atezolizumab according to standard of care and in line with the current SmPC or local labelling; Receiving concomitant systemic anticancer therapy at the time of initiation of Atezolizumab or an Atezolizumab-containing regimen for treatment of the same disease, as per label; Receiving treatment with Atezolizumab as part of a clinical trial, pre-approval access program, compassionate use program, expanded use program, post-trial access program, or continued access program; Unwilling to complete questionnaires related to treatment satisfaction and treatment-related quality of life.